相关实验视频
Updated: Jun 9, 2025

Strategies for Assessing Autistic-Like Behaviors in Mice
Published on: September 20, 2024
对组合治疗的价值赋值框架
Andrew H Briggs1, Alexis Doyle-Connolly2, John Schneider2
1London School of Hygiene and Tropical Medicine, London, UK; Avalon Health Economics, Morristown, NJ, USA.
一个新的价值赋值框架有助于在组合疗法中的组件治疗之间分配价值. 这确保了临床上有益的组合治疗的公平定价和融资决策.
科学领域:
- 卫生经济学 卫生经济学
- 卫生技术评估 卫生技术评估
- 制药政策 制药政策 制药政策
背景情况:
- 成本效益分析 (CEA) 对于政策决策至关重要.
- 当骨干治疗接近支付意愿值时,评估组合疗法会带来挑战.
- 缺乏价值赋值机制可能会低估有益的组合治疗.
研究的目的:
- 开发一种价值赋值方法,用于将价值分配到组合治疗的组件之间.
- 解决与既有治疗方法一起使用的新疗法的定价和补偿方面的挑战.
主要方法:
- 基于标准的CEA决策规则.
- 包含完美/不完美的单疗效果信息.
- 制造商之间的平衡/不平衡市场力量的帐户.
主要成果:
- 增值价值的份额取决于信息的可用性和市场力量.
- 场景需要在定义范围内的增值价值份额的谈判.
- 该框架为价值分配提供了一个结构化的方法.
结论:
- 价格独立的价值赋值框架是可行的.
- 专注于通过质量调整的生命年 (QALY) 收益量化的福利.
- 支持卫生技术评估机构评估新型组合治疗.
更多相关视频
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
13:04Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
Published on: September 19, 2012
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Attribution Theory
Framing Effects
Fundamental Attribution Error
Strategies for Assessing and Addressing Confounding
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...